Illumina, Inc. (NASDAQ:ILMN) Shares Bought by Bank of Montreal Can

Bank of Montreal Can increased its stake in Illumina, Inc. (NASDAQ:ILMN) by 6.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 151,254 shares of the life sciences company’s stock after purchasing an additional 8,730 shares during the quarter. Bank of Montreal Can’s holdings in Illumina were worth $19,681,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Tidal Investments LLC increased its stake in shares of Illumina by 51.2% during the first quarter. Tidal Investments LLC now owns 9,901 shares of the life sciences company’s stock valued at $1,361,000 after acquiring an additional 3,352 shares during the period. Comerica Bank increased its position in shares of Illumina by 22.2% during the 1st quarter. Comerica Bank now owns 32,070 shares of the life sciences company’s stock valued at $4,404,000 after purchasing an additional 5,819 shares during the period. Virtu Financial LLC bought a new stake in shares of Illumina in the 1st quarter worth $271,000. Atria Investments Inc raised its stake in shares of Illumina by 72.6% in the 1st quarter. Atria Investments Inc now owns 21,165 shares of the life sciences company’s stock worth $2,906,000 after buying an additional 8,902 shares in the last quarter. Finally, Cetera Investment Advisers lifted its holdings in shares of Illumina by 361.1% in the first quarter. Cetera Investment Advisers now owns 14,617 shares of the life sciences company’s stock valued at $2,007,000 after buying an additional 11,447 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Trading Down 0.1 %

NASDAQ ILMN opened at $144.15 on Friday. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94. Illumina, Inc. has a 1-year low of $99.23 and a 1-year high of $156.66. The firm’s fifty day simple moving average is $141.88 and its 200-day simple moving average is $125.88. The company has a market capitalization of $22.86 billion, a PE ratio of -14.47 and a beta of 1.13.

Illumina (NASDAQ:ILMN) last issued its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.26. The company had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The business’s revenue was down 3.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.33 EPS. As a group, sell-side analysts anticipate that Illumina, Inc. will post 4.11 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ILMN. Hsbc Global Res upgraded shares of Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price objective for the company in a research report on Thursday, October 17th. TD Cowen raised their target price on shares of Illumina from $166.00 to $177.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Royal Bank of Canada upped their price target on Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a report on Tuesday, November 5th. Argus raised Illumina from a “hold” rating to a “buy” rating and set a $150.00 price objective for the company in a research note on Wednesday, August 28th. Finally, Scotiabank cut their target price on Illumina from $176.00 to $164.00 and set a “sector outperform” rating on the stock in a research report on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $164.00.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.